Gene expression tests are guiding critical treatment decisions in early‑stage breast cancer. Using genomic testing for breast cancer recurrence, you can avoid under or over treatment and the life-changing impact these choices can have on a woman’s life – now and in years to come.
EndoPredict Breast Cancer Prognostic Test is the most accurate gene expression test for early-stage breast cancer recurrence to help you make treatment decisions for your eligible ER positive/HER2 negative primary invasive breast cancer patients.1,2
Myriad Genetics is committed to illuminating the treatment pathway for every woman
EndoPredict predicts the individual chemotherapy benefit for women with ER positive/HER2 negative early-stage breast cancer, so confident treatment decisions can be made with your patients.3
EndoPredict provides an accurate assessment for risk of breast cancer recurrence within 10 years, allowing you and your patients to make confident systemic therapy decisions together.4
EndoPredict is the only test able to predict risk of recurrence up to 15 years, allowing you to predict the future and make safe choices with your patients today.5
EndoPredict gives important information to guide early treatment decisions for women with invasive primary breast cancer that is:
EndoPredict is the ONLY second generation breast cancer recurrence gene expression test validated for premenopausal as well as postmenopausal women.2-8
Learn more about EndoPredict’s superior accuracy and prognostic performance.
Validated in five prospective-retrospective studies of more than 3,500 patients.2-8
Data released at SABCS 2021 from a prospective randomized phase III study confirm the accuracy and prognostic power of EndoPredict, particularly in node positive patients.9,10
EndoPredict is recommended by many international and national guidelines, including ASCO, NCCN, AJCC, ESMO, St. Gallen, EGTM, AGO, HAS, NICE, SEOM, AIOM, CACA-CBCS, CcO.
EndoPredict Breast Cancer Prognostic Test is the only second generation breast cancer recurrence gene expression test validated for premenopausal AND postmenopausal women.2-8
EndoPredict Breast Cancer Prognostic Test is the only second generation test with level of evidence 1A9,10 for node positive breast cancer. The test is validated to accurately identify node positive breast cancer patients with true low-risk of cancer recurrence, allowing more of your patients to safely avoid adjuvant chemotherapy.2-8
For node negative patients, EndoPredict correctly identifies a large group at low-risk BUT also classifies high-risk patients who can benefit from chemotherapy.2,5
EndoPredict Breast Cancer Prognostic Test provides clear, fast and actionable results for every woman with ER positive/HER2 negative early-stage breast cancer.
Learn how to interpret the EndoPredict report
EndoPredict Breast Cancer Prognostic Test is available to order by clinicians via numerous local labs in your country or outside of the EU also via Myriad Genetics’ central laboratory in Salt Lake City, USA.
Find your local lab
Contact your local pathology lab offering EndoPredict. This offers the fastest turnaround time for an EndoPredict test.
Send your sample
You can take tumor samples from a biopsy or surgical specimen and simply send to your local lab. The lab will provide further information on preparing and sending the sample.
Results in days
Once the lab has received your sample, results can be returned within a few days, allowing you and your patient to make important treatment decisions without delay.